Interferon alfa therapy in CALR-mutated essential thrombocythemia

N Engl J Med. 2014 Jul 10;371(2):188-9. doi: 10.1056/NEJMc1401255.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Calreticulin / genetics*
  • Female
  • Humans
  • Immunologic Factors / therapeutic use*
  • Interferon-alpha / therapeutic use*
  • Janus Kinase 2 / genetics
  • Male
  • Middle Aged
  • Mutation*
  • Thrombocythemia, Essential / drug therapy*
  • Thrombocythemia, Essential / genetics

Substances

  • Calreticulin
  • Immunologic Factors
  • Interferon-alpha
  • Janus Kinase 2